Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAU 2022 | Biomarkers associated with PARPi response in patients with castration-resistant prostate cancer

Joe O'Sullivan • 28 Jun 2022
EAU 2022
Genitourinary Cancer Prostate Cancer Olaparib Rucaparib

Joe O’Sullivan, MD, Queen’s University, Belfast, UK, explores biomarkers in association with benefit to PARP inhibitors (PARPi) in patients with castration-resistant prostate cancer, including BRCA mutation status. Dr O’Sullivan talks on the importance of developing novel PARP inhibitors that show increased efficacy and reduced toxicity. This interview took place at the European Association of Urology (EAU) Meeting 2022.

Disclosures

Prof. O’Sullivan reports the following conflicts of interest:
Personal fees for Advisory Board and Speaker’s bureau from: AAA/Novartis, Astellas, Bayer, Janssen, Sanofi

More from Joe O'Sullivan

Recent advances in mHSPC: 177Lu-PSMA-617, PROpel and biomarker-directed strategies
1:37
Recent advances in mHSPC: 177Lu-PSMA-617, PROpel and biomarker-directed strategies
Joe O'Sullivan • 28 Jun 2022
Role of the addition of docetaxel to ADT in mHSPC
1:19
Role of the addition of docetaxel to ADT in mHSPC
Joe O'Sullivan • 28 Jun 2022
UK prostate cancer challenges
1:26
UK prostate cancer challenges
Joe O'Sullivan • 8 Mar 2019
AdRad safety results: radium-223/VMAT RT in the first-line for metastatic prostate cancer
1:30
AdRad safety results: radium-223/VMAT RT in the first-line for metastatic prostate cancer
Joe O'Sullivan • 8 Mar 2019

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals